Beta Drugs Quarterly Results for Trading Insights
In Sept 2025, Beta Drugs (BETA) reported revenue ₹106 Cr and net profit ₹12 Cr. For annual financials, live price and key ratios, visit BETA company profile.
Latest Quarter Net Profit
₹12 Cr
QSept 2025
BETA Quarterly Results — Revenue, Profit & EPS Highlights
Beta Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with BETA DCF to assess whether the stock is under or overvalued.
- Revenue of ₹106 Cr in Sept 2025 (+8.2% vs Mar 2025)
- Net Profit of ₹12 Cr in Sept 2025 (+33.3% vs Mar 2025)
- EBITDA of ₹24 Cr in Sept 2025 (+26.3% vs Mar 2025)
- Operating Margin of 21.0% in Sept 2025 (+5.0pp vs Mar 2025)
- Earnings Per Share of ₹12.10 in Sept 2025 (+35.2% vs Mar 2025)
Beta Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BETA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 106 | 98 | 103 | 90 | 89 | 8.2% | - |
| Net Profit (₹ Cr) | 12 | 9 | 12 | 9 | 9 | - | - |
| EBITDA (₹ Cr) | 24 | 19 | 23 | 19 | 17 | - | - |
| EPS (₹) | 12.10 | 8.95 | 11.59 | 8.40 | 9.31 | - | - |
| Operating Margin (%) | 21.0% | 16.0% | 20.0% | 19.0% | 18.0% | - | - |
BETA Share Price Trend — 1-Year Movement Across Quarterly Results
Beta Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse Beta Drugs shareholding analysis to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Dec 2025
90
Jun 2025
103
Mar 2025
98
Sept 2025
106
Net Profit Trend (₹ Cr)
Dec 2025
9
Jun 2025
12
Mar 2025
9
Sept 2025
12
Operating Margin Trend (%)
Dec 2025
19.0%
Jun 2025
20.0%
Mar 2025
16.0%
Sept 2025
21.0%
BETA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Beta Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1652.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 127.1 |
|
Divis Laboratories
Sept 2025 |
₹162,373.86 Cr | 6070.0 | 2,860 | 689 | +7.1% | - | 24.1% | 233.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4181.0 | 3,219 | 591 | +11.3% | - | 18.4% | 238.4 |
|
Lupin
Sept 2025 |
₹106,664.75 Cr | 2315.1 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.5 |
|
Dr Reddys Laborator…
Sept 2025 |
₹102,844.71 Cr | 1235.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores